Maravai LifeSciences Expands Its Intellectual Property Portfolio
Maravai LifeSciences, Inc. recently announced the United States Patent and Trademark Office has issued a new patent, United States Patent No. 10,913,768, to the company’s TriLink Biotechnologies subsidiary.
The patent covers advancements in TriLink’s CleanCap technology for the co-transcriptional capping of messenger RNAs (mRNAs). This patent is the third US patent that has issued to the company related to the CleanCap technology. Capping is an important step in the production of synthetic mRNA, which is used to develop nucleic acid vaccines and therapeutics that deliver instructions to human cells to produce proteins that may prevent or correct disease.
The technology described by United States Patent No. 10,913,768 facilitates the production of mRNAs and provides a significant improvement over legacy co-transcriptional capping methods.
“Capping is a critical process in creating viable mRNA constructs that remain biologically active without eliciting immune responses,” explained Mike Houston, PhD, Chief Scientific Officer of Maravai. “By changing the capping approach and streamlining the manufacturing workflow, we deliver a novel solution, whether customers purchase CleanCap in bulk for their own mRNA development programs or utilize mRNA synthesized by TriLink BioTechnologies that already incorporates this novel capping technology.”
CleanCap overcomes many drawbacks of existing approaches, enabling highly efficient, reproducible production of capped mRNA. CleanCap technology allows capping to occur in a single reaction, streamlining the manufacturing of mRNA at large scales. Reduced manufacturing time is critical for a number of emerging applications, such as the development of personalized cancer therapeutics and during rapid vaccine responses to pandemics. CleanCap also reduces the cost of mRNA manufacturing, further accelerating the adoption of new mRNA therapeutics.
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines o support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis, bioprocess impurity detection and analysis, and protein labeling and detection to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.
TriLink BioTechnologies, part of Maravai LifeSciences, is a CDMO helping life science leaders and innovators overcome challenges in the synthesis and scale-up of nucleic acids, NTPs and mRNA capping analogs with scale-up expertise and unique mRNA production capabilities, including its proprietary CleanCap mRNA capping technology. TriLink continues to expand its cGMP and general manufacturing capacity at its new global headquarters to support mRNA, oligonucleotide & DNA plasmid therapeutic, vaccine and diagnostic customers. For more information, visit www.trilinkbiotech.com
Total Page Views: 373